BRPI0309631A2 - vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4 - Google Patents

vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4

Info

Publication number
BRPI0309631A2
BRPI0309631A2 BRPI0309631A BRPI0309631A BRPI0309631A2 BR PI0309631 A2 BRPI0309631 A2 BR PI0309631A2 BR PI0309631 A BRPI0309631 A BR PI0309631A BR PI0309631 A BRPI0309631 A BR PI0309631A BR PI0309631 A2 BRPI0309631 A2 BR PI0309631A2
Authority
BR
Brazil
Prior art keywords
dengue
utr
trivial
nucleotides
deletion
Prior art date
Application number
BRPI0309631A
Other languages
English (en)
Inventor
Barry Falgout
Joseph Blaney
Kathryn Hanley
Lewis Markoff
Stephen S Whitehead
Original Assignee
Government Of The United Of America As Represented By The Secretary Of The Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The United Of America As Represented By The Secretary Of The Health And Human Services filed Critical Government Of The United Of America As Represented By The Secretary Of The Health And Human Services
Publication of BRPI0309631A2 publication Critical patent/BRPI0309631A2/pt
Publication of BRPI0309631A8 publication Critical patent/BRPI0309631A8/pt
Publication of BRPI0309631B1 publication Critical patent/BRPI0309631B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
BRPI0309631-9A 2002-05-03 2003-04-25 Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição BRPI0309631B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37786002P 2002-05-03 2002-05-03
US60/377,860 2002-05-03
US43650002P 2002-12-23 2002-12-23
US60/436,500 2002-12-23
PCT/US2003/013279 WO2003092592A2 (en) 2002-05-03 2003-04-25 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4

Publications (3)

Publication Number Publication Date
BRPI0309631A2 true BRPI0309631A2 (pt) 2016-11-01
BRPI0309631A8 BRPI0309631A8 (pt) 2018-09-25
BRPI0309631B1 BRPI0309631B1 (pt) 2021-07-20

Family

ID=29406814

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309631-9A BRPI0309631B1 (pt) 2002-05-03 2003-04-25 Composição imunogênica tetravalente compreendendo vírus atenuado contra dengue e vacina tetravalente compreendendo a dita composição

Country Status (15)

Country Link
US (7) US7517531B2 (pt)
EP (5) EP1554301B1 (pt)
JP (1) JP4977811B2 (pt)
AT (1) ATE481982T1 (pt)
BR (1) BRPI0309631B1 (pt)
CA (1) CA2483653C (pt)
CY (1) CY1120558T1 (pt)
DE (1) DE60334310D1 (pt)
DK (2) DK2338508T3 (pt)
ES (2) ES2355719T3 (pt)
HU (1) HUE037330T2 (pt)
PT (2) PT1554301E (pt)
SI (2) SI1554301T1 (pt)
TR (1) TR201806655T4 (pt)
WO (1) WO2003092592A2 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037330T2 (hu) * 2002-05-03 2018-08-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
RU2465326C2 (ru) 2005-04-24 2012-10-27 Санофи Пастер Байолоджикс Ко Рекомбинантные флавивирусные вакцины
JP4549224B2 (ja) * 2005-04-25 2010-09-22 出光ユニテック株式会社 透明ポリプロピレン系樹脂シートの製造方法、透明ポリプロピレン系樹脂シート、及び成形品、並びに透明ポリプロピレン系樹脂シートからなる成形品の白化防止方法、及び温度判別方法
BRPI0613287A2 (pt) 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
US8017754B2 (en) 2005-07-22 2011-09-13 Research Development Foundation Attenuated virus strains and uses thereof
AU2016219680B2 (en) * 2006-08-15 2018-08-09 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
EP2589602B1 (en) * 2006-08-15 2016-04-06 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of dengue virus vaccine components
AU2013263788B2 (en) * 2006-08-15 2016-05-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
TWI472639B (zh) 2009-05-22 2015-02-11 Samsung Display Co Ltd 薄膜沉積設備
JP5623786B2 (ja) 2009-05-22 2014-11-12 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置
KR101117719B1 (ko) * 2009-06-24 2012-03-08 삼성모바일디스플레이주식회사 박막 증착 장치
JP5328726B2 (ja) 2009-08-25 2013-10-30 三星ディスプレイ株式會社 薄膜蒸着装置及びこれを利用した有機発光ディスプレイ装置の製造方法
JP5677785B2 (ja) 2009-08-27 2015-02-25 三星ディスプレイ株式會社Ｓａｍｓｕｎｇ Ｄｉｓｐｌａｙ Ｃｏ．，Ｌｔｄ． 薄膜蒸着装置及びこれを利用した有機発光表示装置の製造方法
US8999675B2 (en) * 2009-08-31 2015-04-07 Gen-Probe Incorporated Dengue virus assay
US8876975B2 (en) 2009-10-19 2014-11-04 Samsung Display Co., Ltd. Thin film deposition apparatus
KR101084184B1 (ko) 2010-01-11 2011-11-17 삼성모바일디스플레이주식회사 박막 증착 장치
KR101174875B1 (ko) 2010-01-14 2012-08-17 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101193186B1 (ko) 2010-02-01 2012-10-19 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101156441B1 (ko) 2010-03-11 2012-06-18 삼성모바일디스플레이주식회사 박막 증착 장치
KR101202348B1 (ko) 2010-04-06 2012-11-16 삼성디스플레이 주식회사 박막 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
US8894458B2 (en) 2010-04-28 2014-11-25 Samsung Display Co., Ltd. Thin film deposition apparatus, method of manufacturing organic light-emitting display device by using the apparatus, and organic light-emitting display device manufactured by using the method
IT1400574B1 (it) 2010-05-06 2013-06-14 Freni Brembo Spa Dispositivo di frenatura a disco per veicoli
US8685649B2 (en) * 2010-06-10 2014-04-01 The United States Of America As Represented By The Secretary Of The Navy RT-LAMP assay for the detection of pan-serotype dengue virus
KR101223723B1 (ko) 2010-07-07 2013-01-18 삼성디스플레이 주식회사 박막 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
EP2621525A4 (en) * 2010-10-01 2015-01-14 Univ Rochester Flavivirus DOMAIN III VACCINE
KR101738531B1 (ko) 2010-10-22 2017-05-23 삼성디스플레이 주식회사 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
KR101723506B1 (ko) 2010-10-22 2017-04-19 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR20120045865A (ko) 2010-11-01 2012-05-09 삼성모바일디스플레이주식회사 유기층 증착 장치
US20120294889A1 (en) * 2010-11-12 2012-11-22 Paxvax, Inc. Chimeric Flavivirus Vaccines
KR20120065789A (ko) 2010-12-13 2012-06-21 삼성모바일디스플레이주식회사 유기층 증착 장치
KR101760897B1 (ko) 2011-01-12 2017-07-25 삼성디스플레이 주식회사 증착원 및 이를 구비하는 유기막 증착 장치
KR101840654B1 (ko) 2011-05-25 2018-03-22 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101852517B1 (ko) 2011-05-25 2018-04-27 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 디스플레이 장치의 제조 방법
KR101857249B1 (ko) 2011-05-27 2018-05-14 삼성디스플레이 주식회사 패터닝 슬릿 시트 어셈블리, 유기막 증착 장치, 유기 발광 표시장치제조 방법 및 유기 발광 표시 장치
KR101826068B1 (ko) 2011-07-04 2018-02-07 삼성디스플레이 주식회사 유기층 증착 장치
KR20130004830A (ko) 2011-07-04 2013-01-14 삼성디스플레이 주식회사 유기층 증착 장치 및 이를 이용한 유기 발광 표시 장치의 제조 방법
KR102015872B1 (ko) 2012-06-22 2019-10-22 삼성디스플레이 주식회사 유기층 증착 장치, 이를 이용한 유기 발광 디스플레이 장치의 제조 방법 및 이에 따라 제조된 유기 발광 디스플레이 장치
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
SG11201500439RA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR102081284B1 (ko) 2013-04-18 2020-02-26 삼성디스플레이 주식회사 증착장치, 이를 이용한 유기발광 디스플레이 장치 제조 방법 및 유기발광 디스플레이 장치
MY187896A (en) * 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
NO340722B1 (no) * 2014-06-27 2017-06-06 Norwegian Institute For Agricultural & Environmental Res Transgene planter som uttrykker et rekombinant tetravalent kimært denguevirusantigen for å fremstille effektive vaksiner avledet derfra, samt transgent plastid, plantecelle og frø, rekombinant DNA molekyl, vektor, fremgangsmåter for fremstilling og anvendelse derav
MX383329B (es) 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
MY200888A (en) 2015-09-30 2024-01-22 Panacea Biotec Ltd Stable Live Attenuated Recombinant Dengue Vaccine
US11285202B2 (en) * 2016-01-26 2022-03-29 University Of South Carolina Polymer-protein core-shell particles as effective vaccine delivery vehicles and treatments methods using the same
AU2017230112A1 (en) 2016-03-11 2018-10-04 The Johns Hopkins University Live attenuated Zika virus vaccine
MY192806A (en) * 2016-04-13 2022-09-09 Takeda Vaccines Inc Compositions and methods of vaccination against dengue virus in children and young adults
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
BR112020011205A8 (pt) 2017-12-07 2023-02-07 Merck Sharp & Dohme Formulações de composições de vacina contra o vírus da dengue
EP3846848A4 (en) * 2018-09-04 2022-07-06 The Board of Regents of the University of Texas System DNA PLASMID INITIATED LIVE VACCINES FOR PLUS-POLARITY SINGLE STRAND RNA VIRUS
WO2021173597A1 (en) * 2020-02-28 2021-09-02 Merck Sharp & Dohme Corp. Dengue serotype specific rt-pcr multiplex assay
EP4482520A1 (en) * 2022-02-22 2025-01-01 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776638B2 (en) * 1999-03-26 2004-09-16 Walter Reed Army Institute Of Research Adaptation of virus to vertebrate cells
EP1159969A1 (fr) * 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
EP2290108B1 (en) * 2001-05-22 2014-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
HUE037330T2 (hu) * 2002-05-03 2018-08-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
EP2589602B1 (en) * 2006-08-15 2016-04-06 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Development of dengue virus vaccine components

Also Published As

Publication number Publication date
EP3205352A1 (en) 2017-08-16
EP2338508B1 (en) 2018-02-14
EP1554301A2 (en) 2005-07-20
EP1554301B1 (en) 2010-09-22
EP2319532A1 (en) 2011-05-11
WO2003092592A2 (en) 2003-11-13
USRE46631E1 (en) 2017-12-12
TR201806655T4 (tr) 2018-06-21
US20180010099A1 (en) 2018-01-11
US9783787B2 (en) 2017-10-10
EP3763382A1 (en) 2021-01-13
BRPI0309631B1 (pt) 2021-07-20
ES2355719T3 (es) 2011-03-30
BRPI0309631A8 (pt) 2018-09-25
ATE481982T1 (de) 2010-10-15
US20130011433A1 (en) 2013-01-10
US20070009552A1 (en) 2007-01-11
DK1554301T3 (da) 2011-01-24
JP2005532044A (ja) 2005-10-27
US20200392469A1 (en) 2020-12-17
SI1554301T1 (sl) 2011-01-31
ES2677348T3 (es) 2018-08-01
CA2483653A1 (en) 2003-11-13
WO2003092592A3 (en) 2005-05-19
EP2338508A1 (en) 2011-06-29
US20090258036A1 (en) 2009-10-15
DK2338508T3 (en) 2018-05-28
JP4977811B2 (ja) 2012-07-18
CY1120558T1 (el) 2019-07-10
SI2338508T1 (en) 2018-07-31
USRE46641E1 (en) 2017-12-19
US10837003B2 (en) 2020-11-17
DE60334310D1 (de) 2010-11-04
PT2338508T (pt) 2018-05-16
CA2483653C (en) 2014-10-28
US7517531B2 (en) 2009-04-14
EP1554301A4 (en) 2006-11-08
US11753627B2 (en) 2023-09-12
HUE037330T2 (hu) 2018-08-28
AU2003231185A1 (en) 2003-11-17
PT1554301E (pt) 2010-12-28
US8075903B2 (en) 2011-12-13

Similar Documents

Publication Publication Date Title
BRPI0309631A2 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31' dos tipos de dengue 1,2,3,e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
DE60329367D1 (de) Verwendung bei der bekämpfung von hepatitis c virusinfektion
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
LU91328I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
LU92749I2 (fr) Composition comprenant le virus de la diarrhée virale bovine atténué 1(bvdv-1) et le virus de la diarrhée virale bovine atténué 2 (bvdv-2)
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
UA85536C2 (en) Viral antigens
DK1181027T3 (da) Diætetisk eller farmaceutisk præparat til anvendelse til forebyggelsen eller behandling af hyperoxaluri
EP1545599A4 (en) IMMUNOGENIC COMPOSITIONS AND ITS DIAGNOSTIC AND THERAPEUTIC USES
EP1307130A4 (en) VACCINE AGAINST THE VIRUS OF HUMAN IMMUNODEFICIENCY
NO992102D0 (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
NO20030296L (no) Heparinavledede polysakkaridblandinger, deres fremstilling samt farmasöytiske preparater inneholdende blandingene
DE60033043D1 (de) Modifizierte pflanzenviren und deren verwendungsmethoden
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
FR2822154B1 (fr) Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
MA29030B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
IL200747A0 (en) Subunits of the enteritis hemorrhagic virus fiber protein and uses thereof as vaccines
EP1575601A4 (en) RECOMBINANT VACCINE VIRUSES EXPRESSING IL-15, AND METHOD OF USE THEREOF
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
EP1570067A4 (en) METHODS AND COMPOSITIONS FOR IMMUNIZING AGAINST HIV
FR15C0084I2 (fr) Vaccin contre les virus hpv16 et hpv18 et au moins un autre type de hpv selectionne parmi hpv 31, 45 ou 52
NO20033829L (no) Virusdrepende preparater
ATE437656T1 (de) Impfstoff gegen das maul- und klauensäure-virus

Legal Events

Date Code Title Description
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 25/04/2023